Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.75 |
| ▸ | CASR | P41180 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8715644 | 1.00 | HSD17B10 (0.75) | HSD17B10CASRLMNAEPHX1MEN1 | |
| SCHEMBL15093717 | 1.00 | HSD17B10 (0.75) | HSD17B10CASRLMNAEPHX1MEN1 | |
| SCHEMBL8715641 | 1.00 | HSD17B10 (0.75) | HSD17B10CASRLMNAEPHX1MEN1 | |
| SCHEMBL13500530 | 0.94 | HSD17B10 (0.68) | HSD17B10CASRLMNAEPHX1MEN1 | |
| SCHEMBL13594604 | 0.90 | HSD17B10 (0.68) | HSD17B10CASRLMNAEPHX1MEN1 | |
| SCHEMBL14288556 | 0.90 | HSD17B10 (0.68) | HSD17B10CASRLMNAEPHX1MEN1 | |
| SCHEMBL13923627 | 0.90 | HSD17B10 (0.68) | HSD17B10CASRLMNAEPHX1MEN1 | |
| SCHEMBL10679562 | 0.88 | HSD17B10 (0.66) | HSD17B10CASRLMNAEPHX1MEN1 | |
| SCHEMBL25336459 | 0.86 | MMP9 (0.66) | HSD17B10LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL247742 | 0.86 | HSD17B10 (0.63) | HSD17B10CASRLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163766-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110118250-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7872009-B2 | Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1954693-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070185103-A1 | Beta-secretase modulators and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007062007-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118250-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | HSD17B10 1966/4885CASR 579/4885LMNA 757/4885 |
| US-20070185103-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | HSD17B10 1966/4885CASR 579/4885LMNA 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.